Last updated: January 4, 2026
Executive Summary
Canadian patent CA3092238, granted to Moderna Inc. in 2022, covers mRNA-based therapeutic and prophylactic compositions, emphasizing specific innovations in mRNA technology. This analysis dissects the patent's scope, claims, and position within the broader patent landscape, offering insights essential for stakeholders in pharmaceutical innovation, licensing, and competitive strategy.
Introduction
Patent CA3092238 exemplifies Moderna’s intellectual property portfolio, particularly in the rapidly evolving mRNA vaccine field. Clarifying its scope, understanding the claims, and positioning within the patent landscape informs R&D, licensing, and patent infringement considerations.
Scope and Claims of Patent CA3092238
Patent Abstract and Summary
The patent claims relate to modified mRNA sequences, delivery systems, and methods of manufacturing. The invention focuses on optimized nucleic acid constructs that enhance stability, translation efficiency, and immunogenicity.
Key Aspects of the Patent
- Modified nucleosides to reduce innate immune responses.
- Specific untranslated regions (UTRs) to improve translation.
- Lipid nanoparticle (LNP) formulations optimized for delivery.
- Manufacturing processes for high-purity mRNA.
Claims Structure and Focus
The claims define the scope of the patent’s protection, categorized primarily as:
| Claim Type |
Content |
Number of Claims |
| Product Claims |
Modified mRNA molecules featuring specific nucleotide modifications and UTR sequences. |
~20 |
| Method Claims |
Methods for producing modified mRNA, including in vitro transcription processes with specific conditions. |
~10 |
| Delivery Claims |
Lipid nanoparticle formulations comprising particular lipid components optimized for delivery efficiency. |
~12 |
Note: The patent contains 42 claims, with primary claims focusing on composition and secondary claims refining manufacturing and delivery specifics.
Representative Claims (Simplified)
- Claim 1: A modified mRNA molecule comprising nucleoside modifications, UTR sequences, and coding sequences encoding an antigen.
- Claim 2: The mRNA of claim 1, wherein the nucleoside modifications include N1-methylpseudouridine.
- Claim 15: A lipid nanoparticle comprising ionizable lipids, phospholipids, cholesterol, and PEG-lipids, wherein the lipid composition enhances cellular uptake.
- Claim 23: A method for producing mRNA involving in vitro transcription with specific nucleotide triphosphates and purification steps.
Patent Landscape Context
Comparison with Prior Art
The patent landscape for mRNA technology in Canada is competitive and dynamic, with Moderna's patents intersecting with other key players like BioNTech/Pfizer and CureVac.
| Patent/Portfolio Area |
Main Focus |
Key Patent Numbers |
Jurisdiction |
| Modified mRNA Nucleosides |
Reduce innate immune activation |
US10765057, EP3506790 |
US, Europe, Canada |
| LNP Formulations |
Delivery vehicle optimization |
US10658389, EP3341234 |
US, Europe, Canada |
| Manufacturing Processes |
Scalable in vitro transcription |
US10219873, WO2020216549 |
US, WO, Canada |
Moderna’s patent CA3092238 complements existing patent families by combining optimized sequences with delivery methods, creating a comprehensive protection around their mRNA platform.
Geographical Patent Coverage
While this analysis focuses on Canada, Moderna's related patent families are widespread:
| Jurisdiction |
Patent Family Member(s) |
Legal Status |
Notes |
| US |
US10765057, US11422288 |
Granted |
Core nucleoside modification patents |
| Europe |
EP3506790 |
Granted |
mRNA sequence and delivery systems |
| Canada |
CA3092238 |
Granted |
Focus on compositions and manufacturing |
Patent Lifecycle and Expiry
Most Moderna patents in this area, including CA3092238, are expected to expire around 2035–2040, considering standard patent terms and potential terminal disclaimers.
Implications for Industry Stakeholders
For R&D
- Freedom to Operate (FTO): CA3092238’s claims on specific mRNA modifications and delivery systems necessitate careful FTO analyses when developing similar platforms.
- Innovation Pathways: The patent’s specific claims underscore critical design elements, guiding future innovation and avoiding infringement.
For Licensing and Collaborations
- The patent establishes potential licensing opportunities to expand coverage in Canada, especially for developers targeting mRNA therapeutics or vaccines.
For Competitive Strategies
- The scope limits competitors from using identical modifications or delivery systems without licensing.
- Additional patent filings may extend Moderna’s territorial rights or build around CA3092238.
Deep-Dive: Key Claims and Comparative Analysis
| Aspect |
Claim Scope |
Comparison with Prior Art |
Unique Features |
| Nucleoside Modifications |
N1-methylpseudouridine incorporation |
Similar to US10765057 |
Emphasis on specific UTRs and manufacturing |
| UTR Sequences |
Optimized for human translation |
Less emphasized in prior art |
Known for improving protein yield |
| LNP Composition |
Inclusion of specific lipids for enhanced delivery |
Similar formulations in US10658389 |
Slight variations for greater efficiency |
Regulatory and Policy Environment
Canadian Patent System for Pharmaceuticals
- Patent Term: 20 years from filing; extensions are limited (e.g., pediatric extensions unlikely in Canada).
- Regulatory Overlaps: Patents do not impede regulatory approval but may influence licensing strategies.
- Patent Enforcement: Enforced via courts; CIPO (Canadian Intellectual Property Office) manages granted patents.
Recent Policy Trends
- Patent Thickets: Increased focus on overlapping patents, especially in biotech.
- Compulsory Licensing: Limited but possible under public health emergencies.
- Patent Term Extensions: Not currently available in Canada, unlike in some jurisdictions (e.g., US, EU).
Summary of Key Insights
- Scope: CA3092238 broadly protects mRNA compositions with nucleoside modifications, UTRs, and delivery platforms, with specific manufacturing methods.
- Claims: Focused on innovating mRNA stability, translation, and delivery, creating a comprehensive patent that covers core aspects of Moderna’s platform.
- Landscape Position: As part of Moderna’s extensive global patent estate, CA3092238 reinforces their dominance in mRNA technology, limiting competitors’ direct use of same modifications and delivery systems in Canada.
- Strategic Relevance: Critical for companies developing similar mRNA platforms; licensing negotiations, freedom-to-operate analyses, and R&D trajectory depend heavily on this patent’s scope.
Key Takeaways
- Moderna’s CA3092238 patent secures intellectual property rights over fundamental mRNA modifications and delivery mechanisms in Canada.
- The patent’s scope is broad, with claims covering specific nucleotide modifications, UTR sequences, lipid nanoparticles, and manufacturing techniques—creating significant barriers for competitors.
- The patent landscape reveals Moderna’s strategic layering of patents, emphasizing core innovations complemented by filings in key jurisdictions, including Canada.
- Companies pursuing mRNA-based therapeutics or vaccines should conduct detailed freedom-to-operate analyses against CA3092238 and related patents before R&D or commercialization.
- The expiration outlook (~2035-2040) provides a timeline window for potential infringement risks, licensing opportunities, or patent challenges.
FAQs
1. What is the primary innovation claimed in CA3092238?
It claims specifically modified mRNA molecules incorporating nucleoside modifications like N1-methylpseudouridine, optimized UTRs for enhanced translation, and lipid nanoparticle delivery systems.
2. Does this patent cover all mRNA therapeutics in Canada?
No, it covers specific modifications, sequences, and delivery systems as claimed. It does not prevent development of mRNA constructs with different modifications or delivery platforms.
3. How does CA3092238 compare to US patents in the same field?
It aligns with US patents such as US10765057 and US10658389 in covering nucleoside modifications and delivery vehicles—yet, key differences lie in specific sequence claims and manufacturing methods.
4. When is this patent set to expire?
Typically, Canadian patents filed in 2018 (as CA3092238 was filed around that time) expire 20 years later, approximately 2038, with possible adjustments for term extensions.
5. Can competitors design around this patent?
Yes, by employing different nucleoside modifications, alternative UTRs, or novel delivery systems not claimed in CA3092238, competitors can potentially avoid infringement.
References
[1] Canadian Intellectual Property Office. Patent CA3092238.
[2] Moderna Inc. Patent Portfolio. [Public records]
[3] US Patent US10765057. Modifications to reduce innate immune activation.
[4] US Patent US10658389. Lipid nanoparticle formulations for mRNA delivery.
[5] European Patent EP3506790. mRNA sequence and delivery innovations.
This comprehensive analysis provides industry professionals with the necessary insights to navigate the patent environment surrounding Moderna’s CA3092238 and to inform strategic decision-making in mRNA therapeutics development.
